Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 14/20 | 0.43 |
| ▸ | TRPC4 | Q9UBN4 | 2/20 | 0.39 |
| ▸ | TRPC5 | Q9UL62 | 2/20 | 0.39 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | USP1 | O94782 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20656196 | 0.96 | MDM2 (0.39) | MDM2TRPC4TRPC5TRPC1P2RX3 | |
| SCHEMBL24095545 | 0.93 | TRPC5 (0.38) | MDM2TRPC4TRPC5TRPC1P2RX3 | |
| SCHEMBL20652731 | 0.93 | PKM (0.40) | MDM2TRPC4TRPC5TRPC1P2RX3 | |
| SCHEMBL20652803 | 0.93 | P2RX3 (0.41) | TRPC4TRPC5TRPC1P2RX3KCNH2 | |
| SCHEMBL24095606 | 0.92 | MDM2 (0.43) | MDM2P2RX3GPBAR1USP1 | |
| SCHEMBL20652804 | 0.92 | P2RX3 (0.46) | TRPC4TRPC5TRPC1P2RX3KCNH2 | |
| SCHEMBL20653072 | 0.92 | ADORA3 (0.42) | TRPC4TRPC5P2RX3KCNH2USP1 | |
| SCHEMBL20652798 | 0.90 | TRPC4 (0.38) | MDM2TRPC4TRPC5TRPC1P2RX3 | |
| SCHEMBL20656195 | 0.90 | TRPC4 (0.38) | MDM2TRPC4TRPC5TRPC1P2RX3 | |
| SCHEMBL20652951 | 0.89 | FFAR4 (0.36) | MDM2TRPC4TRPC5TRPC1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3652176-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2021-12-15 | — | — | EP | disclosed |
| US-10329292-B2 | Substituted xanthine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| WO-2019011802-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-17 | — | — | WO | disclosed |
| US-20190016722-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329292-B2 | Substituted xanthine derivatives | TRPC5, TRPV1, TRPC4 | MDM2 4354/4885TRPC4 3/4885TRPC5 1/4885 |
| US-20190016722-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPV1 | MDM2 4635/4885TRPC4 2/4885TRPC5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.